We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IMM Immupharma Plc

0.0025 (0.15%)
08 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.0025 0.15% 1.71 450,046 16:35:21
Bid Price Offer Price High Price Low Price Open Price
1.605 1.815 1.66 1.605 1.605
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services -3.81M -0.0114 -1.46 5.53M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:07:51 O 161,632 1.6372 GBX

Immupharma (IMM) Latest News

Immupharma (IMM) Discussions and Chat

Immupharma (IMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-08 16:07:531.64161,6322,646.24O
2023-12-08 15:18:551.6628,695476.34AT
2023-12-08 15:17:501.6652,000863.20O

Immupharma (IMM) Top Chat Posts

Top Posts
Posted at 09/12/2023 08:20 by Immupharma Daily Update
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 1.71p.
Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £5,534,492.
Immupharma has a price to earnings ratio (PE ratio) of -1.46.
This morning IMM shares opened at 1.61p
Posted at 24/11/2023 12:36 by clintdavid1
This is like poker. We have good starting hand -say KQ suited-but it needs improving. The flop needs to do this-say 2 cards in same suit-a K or Q, or A J not suited or J10 not suited etc. In IMM terms, we need to know the trial is going ahead, a company appointed to run it and what progress has been made on others issues such as CIDP, RTW etc.

The final 2 cards-a long time off-the turn and the river (of dreams) will determine whether we have a winning hand-that is drugs actually coming to market and real revenue streams.

SK interested is your name based on E$ C5 chess defence. I used to play in same Hampstead team headed by Penrose, Israel, Cornforth, Blaine et al in the mid 60's. Are you a chess player? Good to see you back in again.
Posted at 14/11/2023 11:30 by nobbygnome
Interesting S_K! You have to say that on past recent history that there is a good chance the trial will be delayed until next year. Plus I’m not sure what sort of spike such an announcement will bring. Since we won’t get the results for 2 years or more, it will just emphasise how far we are from significant data. I think the only development which will move the price is an announcement from left field concerning the other indications and projects
Posted at 09/10/2023 15:01 by lord loads of lolly
The imperialist - I guess it might.

But the time to do what exactly? Buy? Sell? Panic? Fire Tim? Pop to the loo?

Answers on a postcard please.

Clue: Nobody has a clue how this (or any other share) will turn out.
Posted at 31/8/2023 08:23 by lord loads of lolly
Yup, it smacks of desperation when the RNS keeps trying to make out there'll be positive newsflow going forward. And that this in turn SHOULD lead to an improved share price. Let's just look at the past sharing agreements shall we? And I quote directly from the RNS:

"The Sharing Agreement is similar in structure to those undertaken by the Company with Lanstead in February 2016, June 2019, March 2020, December 2021 and August 2022 respectively. The first three of these arrangements have completed their settlement periods. The February 2016 agreement yielded a net gain to ImmuPharma of approximately £0.6 million more than originally subscribed by Lanstead. The June 2019 and March 2020 agreements yielded approximately £0.9 million and £1.0 million less than originally subscribed by Lanstead respectively. The fourth arrangement runs to March 2024 and is currently yielding approximately £1.1 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date. The fifth arrangement runs to August 2024 and is currently yielding approximately £0.3 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date."

So that's five agreements in total, one of which yielded a positive result (+ £0.6m approx). Currently the other four - of which two are already complete - have yielded a cumulative LOSS of £3.3m versus the current share price. WHAT A TRIUMPH!

Given the above, how many private investors are likely to beat a path to the Winterflood Retail Access Platform so they can subscribe to the Retail Offer? Answers on a postcard please. Clue: the answer may be a nice round figure. At least it can't be negative. Unlike the Sharing Agreement outcomes to date.
Posted at 23/6/2023 09:24 by colsmith
Problem is Nobby we just don't know if all three would fail or pass, its an element of luck (on a 1 shot), which is why Supers comment is so practical - there are so many variables as you obviously know. Supers last bit says it all.

I guess on Covid there is now massive info on effects - good and bad, unfortunately the bad only really comes out with real world use, just as it did with Thalidomide (Abstract from link below is interesting in this context). On news - there should be more this year on test and if the test starts some bits in 2024 on progress and maybe the final result, which is why its a good trade unless those in the market have other intentions?

You accept there is a chance the trial will be successful so I guess you agree there is reason to be positive and see trading the churn as a realistic policy!

The problem for IMM is that its a small guy (even with Avion), a big Pharma with P140 would have had more clout with Regulators and if the 1st trial had been done by a big Pharma I suggest things would be quite different on progress. Maybe IMM should have done a deal with a big Pharma, unless of course there is something in the agreement with CNRS to stop that.

Over and out but it seems this is one to watch - corporate action or share price trading opportunities?

From Supers
"and even then one would have to ask was it the increased dosing, or the narrower selection of patients, or something else entirely...?"
Posted at 16/6/2023 07:49 by lee181067
Still no news and share price drifts ...really not sure if i should just get out now
Posted at 08/6/2023 16:59 by lord loads of lolly
Probably 'cos some expected an RNS the day after their scheduled FDA meeting. To be fair to Tim (& I rarely am, 'cos he's useless), he did say those meeting dates were only estimates and that things could slide. And we're quite used to things sliding at IMM (mainly the share price).
Posted at 31/8/2022 08:54 by lord loads of lolly
Thanks nobby. Yes, I meant TRIAL approval. I know you feel drug dosage means it's doomed. Follow up question: based on other companies' share prices where trial approval was granted, what sort of impact would you expect this to have on IMM's share price (if trial approved). And would you anticipate an initial spike, followed by some floating back down. Or is it more likely the share price would steadily gain over the weeks following any trial approval announcement? I should really have asked you all this before jumping in again yesterday, but still interested to know your thoughts.
Posted at 04/8/2022 07:42 by mudbath
Thanks for providing some balance, supernumerary and 1bond.

So much more edifying than the trite "big plunge coming tomorrow morning" and "Tim is a disgrace!" contributions.

The IMM share price might indeed weaken further .
In this event, I would hope to benefit from taking a decent position.
Posted at 12/5/2022 20:46 by mudbath
The IMM share price moves as if on a snakes and ladders board where the trades(or dice)that should determine its ascent or descent apparently having no influence.
Nevertheless, it is a great stock from which to extract a daily margin, as the MMs seem happy to part with the shares in the morning at 5.75p only to seek their return at 6p or above, after lunch.
Immupharma share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |